Status:
UNKNOWN
Hydroxychloroquine in Unexplained Recurrent Pregnancy Loss
Lead Sponsor:
Ain Shams University
Conditions:
Recurrent Pregnancy Loss
Eligibility:
FEMALE
18-35 years
Phase:
PHASE1
Brief Summary
To investigate efficacy and safety of Hydroxychloroquin in improving pregnancy outcome in women with unexplained recurrent pregnancy loss .
Detailed Description
Recurrent pregnancy loss (RPL) remains a significant challenge in obstetrical practice. It is not only emotionally devastating for expectant women but is also medically challenging. Approximately 1-3%...
Eligibility Criteria
Inclusion
- Women aged between 18 and 35 years inclusive.
- Women with at least three previous consecutive miscarriages in the first trimester of pregnancy of unknown origin with no uterine cavity abnormality that might explain recurrent miscarriage at 3D ultrasonography
- Women who have given their informed consent.
- Patient who did received standard treatment and failed in an ongoing pregnancy
Exclusion
- Previous history VTE (venous thromboembolization)
- Persistent positive APL antibodies: lupus anticoagulant and/or APL (anticardiolipin or anticardiolipin IgG or IgM) titers \>99th percentile or \>40 with at least 12 weeks interval between two positive determinations (persistent antibodies) or a specific clinical setting of APS (thrombotic or obstetrical, apart from RM in the first trimester of pregnancy) .
- Known contraindication to a treatment by HCQ (retinopathy, hypersensitivity to chloroquine or HCQ, G6PD deficiency, acute intermittent porphyria, chronic liver or kidney insufficiency, extensive cutaneous psoriasis not controlled by local treatment, significant chronic digestive or haematologic disease) .
- Indication to a treatment by HCQ (rheumatoid arthritis, Lupus, solar eczema) or previous exposure for \>5years to HCQ.
- BMI \> 35
- Condition may have an effect on immune reaction e.g. history of HCV or HBV .
- Endocrinopathies such as ( DM ,thyroid disorders , hyperprolactinemia ) .
- History of hormonal contraception or intrauterine device usage in last 3 months preceeding .
Key Trial Info
Start Date :
March 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2023
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT05237843
Start Date
March 1 2022
End Date
January 1 2023
Last Update
February 14 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.